THURSDAY, MAY 4

Educational Session: Genomics
3:00 pm-5:00 pm
Session Chair: Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada

3:00-3:20 Molecular Tumor Board - Case Presentation
Lillian L. Siu and William C. Hahn

3:20-3:55 Clinical applications: Drug access and design of genotype-specific trials
Lillian L. Siu

3:55-4:30 Opportunities for translational and discovery research: “Next-Gen” genomics
William C. Hahn, Dana-Farber Cancer Institute, Boston, MA

4:30-5:00 Panel Discussion / Questions from audience
Lillian L. Siu and William C. Hahn

Break
5:00 pm-5:30 pm

Welcome and Opening Remarks
5:30 pm-6:00 pm

5:30-6:00 Welcome
Margaret Foti, American Association for Cancer Research, Philadelphia, PA
Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN
Carlos Gil M. Ferreira, D’or Institute for Research and Education, Rio de Janeiro, Brazil

Plenary Session 1: Immune Checkpoints: Successes and What We Have Learned
6:00 pm-7:30 pm
Session Chair: Joao P.B. Viola, Brazilian National Cancer Institute, Rio de Janiero, Brazil

6:00-6:30 Selective pressure by activated T cells identifies de novo and adaptive resistance mechanisms in melanoma
Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA
# PROGRAM

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30-7:00</td>
<td><strong>State of clinical success of immune checkpoints (new preclinical data on anti-PD-1 and ant-PDL-1)</strong>&lt;br&gt;Cristina B. Bonorino, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil</td>
</tr>
<tr>
<td>7:00-7:30</td>
<td><strong>ER stress responses as new immune checkpoints in cancer</strong>&lt;br&gt;Juan R. Cubillos-Ruiz, Weill Cornell Medical College, New York, NY</td>
</tr>
</tbody>
</table>

**Opening Reception**<br>7:45 pm-9:30 pm

---

**FRIDAY, MAY 5**

**Keynote Lecture 1**<br>8:30 am-9:15 am<br>Session Chair: Carlos Gil M. Ferreira, D’or Institute for Research and Education, Rio de Janeiro, Brazil

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30-9:15</td>
<td><strong>The different facets of cervical cancer prevention</strong>&lt;br&gt;Luisa L. Villa, Fundação Faculdade de Medicina de S Paulo, São Paulo, SP, Brazil</td>
</tr>
</tbody>
</table>

**Break**<br>9:15 am-9:45 am

**Plenary Session 2: Tumor Heterogeneity**<br>9:45 am-10:45 am<br>Session Chair: Felipe C. Geyer, Memorial Sloan Kettering Cancer Center, New York, NY

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:45-10:15</td>
<td><strong>The dynamics of cancer cell heterogeneity</strong>&lt;br&gt;Guido Lenz, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil</td>
</tr>
<tr>
<td>10:15-10:45</td>
<td><strong>Intra-tumour genetic heterogeneity</strong>&lt;br&gt;Felipe C. Geyer</td>
</tr>
</tbody>
</table>

**Break**<br>10:45 am-11:00 am
PROGRAM

Plenary Session 3: Hematologic Malignancies
11:00 am-12:30 pm
Session Chair: Eliana Abdelhay, Brazilian National Cancer Institute, Rio de Janiero, Brazil

11:00-11:30  Epigenetic mechanisms in pathogenesis and targeted therapy for B-cell lymphomas
Ari M. Melnick, Weill Cornell Medical College, New York, NY

11:30-12:00  Clinical networking as a tool to improvement of leukemia care and research in developing countries: The experience of the International Consortium on Acute Leukemias (ICAL)
Eduardo Magalhães Rego, University of São Paulo, Sao Paulo, Brazil

12:00-12:30  Novel therapeutic targets in multiple myeloma
Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA

Poster Session A / Lunch
12:30 pm-3:00 pm

Plenary Session 4: Precision Medicine / Targeted and Combination Therapies / Drug Resistance
3:15 pm-4:45 pm
Session Chair: Oscar G. Arrieta, Instituto Nacional de Cancerologia, Mexico City, Mexico

3:15-3:45  A systems approach to rational combination therapy with PARP inhibitors
Gordon B. Mills, The University of Texas MD Anderson Cancer Center, Houston, TX

3:45-4:15  Evolution and clinical impact of co-occurring genetic alterations in lung cancer
Trever G. Bivona, University of California, San Francisco, CA

4:15-4:45  Overcoming drug resistance and tumor heterogeneity in gastrointestinal cancers
Ryan B. Corcoran, Massachusetts General Hospital Cancer Center, Boston, MA

Break
4:45 pm-5:00 pm

Plenary Session 5: Liquid Biopsies/Organoids/PDX
5:00 pm-6:30 pm
Session Chair: Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN

5:00-5:30  Circulating tumor DNA is a “liquid biopsy” for precision medicine: Basic concepts
Anamaria A. Camargo, Ludwig Institute for Research on Cancer, Sao Paulo, Brazil
PROGRAM

5:30-6:00  Patient-derived xenografts and organoids to predict therapeutic response for breast cancer patients
Alana L. Welm, University of Utah Huntsman Cancer Institute, Salt Lake City, UT

6:00-6:30  Title to be announced
Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA

SATURDAY, MAY 6

Keynote Lecture 2
8:30 am-9:15 am
Session Chair: Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN

Defining a cancer dependencies map
William C. Hahn, Dana-Farber Cancer Institute, Boston, MA

Break
9:15 am-9:45 am

Plenary Session 6: DNA Repair and PARP Inhibitors
9:45 am-11:15 am
Session Chair: Dyeison Antonow, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil

9:45-10:15  Targeting DNA repair in cancer therapy
Alan D. D'Andrea, Dana-Farber Cancer Institute, Boston, MA

10:15-10:45  PARP trapping and Schlafen 11 to kill cancer cells
Yves G. Pommier, National Cancer Institute-CCR, Bethesda, MD

10:45-11:15  Methods for defining DNA repair defects in human cancer
Simon N. Powell, Memorial Sloan Kettering Cancer Center, New York, NY

Break
11:15 am-11:30 am
PROGRAM

Plenary Session 7: Hormone-Dependent Cancers and Steroid Receptors
11:30 am-1:00 pm
Session Chair: Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil

11:30-12:00 Lessons for ER+ breast cancer from neoadjuvant endocrine therapy trials
Matthew J. Ellis, Baylor College of Medicine, Houston, TX

12:00-12:30 Targeting DNA repair dysfunction in prostate cancer
Karen E. Knudsen, Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA

12:30-1:00 Targeting DNA repair deficiencies in breast cancer
Samuel Aparicio, BC Cancer Research Centre, Vancouver, BC, Canada

Poster Session B / Lunch
1:00 pm-3:00 pm

Plenary Session 8: Oncogenes and Tumor Suppressors
3:15 pm-4:45 pm
Session Chair: Roger Chammes, University of São Paulo, Sao Paulo, Brazil

3:15-3:45 Strategies to prevent and treat resistance to EGFR inhibitors in lung cancer
Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA

3:45-4:15 Tumor suppressor and tumor maintenance genes
Scott W. Lowe, Memorial Sloan Kettering Cancer Center, New York, NY

4:15-4:45 Long noncoding RNA-mediated RNA editing as a new mechanism of tumor suppressor gene inactivation
Emmanuel Dias-Neto, A.C. Camargo Cancer Center, São Paulo, Brazil

Break
4:45 pm-5:00 pm

Plenary Session 9: Epigenetics
5:00 pm-6:00 pm
Session Chair: Paulo M. Hoff, Centro de Oncologia, São Paulo, Brazil
PROGRAM

5:00-5:30  The promise among the setbacks for epigenetic therapy in solid tumors
Nilofer S. Azad, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

5:30-6:00  Defining cancer specific epigenomic signature associated with glioma progression
Houtan Noushmehr, University of São Paulo, Ribeirao Preto, São Paulo, Brazil

Closing Remarks
6:00 pm-6:15 pm

Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN
Carlos Gil M. Ferreira, D’or Institute for Research and Education, Rio de Janeiro, Brazil